G
Genomenon
Genomenon develops software tools to rapidly and autonomously prioritize data points for decision-making
About Genomenon
Genomenon is a genomic health IT company that provides tools and services for genetic testing labs and pharmaceutical companies. The company's flagship product, the Mastermind Genomic Search Engine, is a comprehensive database of genomic evidence from scientific literature. This tool allows users to search for information on genetic variants, view the supporting evidence, and understand the clinical significance of those variants. The platform is designed to accelerate the process of interpreting genomic data, which is a critical step in diagnosing and treating genetic diseases.
Genomenon's business model is based on providing access to its Mastermind platform through a subscription-based service. They offer different tiers of access depending on the needs of the client, which range from individual researchers to large-scale clinical laboratories and pharmaceutical companies. In addition to its software platform, the company also offers expert curation services, where their team of scientists and curators will manually review and interpret genomic data for clients. This combination of a software-as-a-service (SaaS) platform and specialized consulting services allows Genomenon to cater to a wide range of customers within the genomics market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Ann Arbor, United States
- Employees
- 136
- Open positions
- 7
- Dealroom signal
- 65.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Developer Tools, Biotechnology, Oncology, Drug Development, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, Techbio
- Client focus
- b2b
- Investment activity
- 1 company, latest Jun 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jun 2024 | $6M | $100M | Undisclosed | ↗ |
| SERIES B✓Equity / VC | Mar 2022 | $20M | $80M | Michigan Angel Fund · Spring Mountain Capital · IrishAngels · Green Park & Golf Ventures | ↗ |
Growth signals
Latest recorded traffic for Genomenon is 24K monthly website visits, down 20% over the last three months. Genomenon's team declined 3.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Michigan Angel Fund
InvestMichigan
Invest Detroit
Three Leaf Ventures
National Institutes of Health
Series A11 investors entered at this stage
IrishAngels
Beringea
Spring Mountain Capital
Green Park & Golf Ventures
Red Cedar Ventures
Atain specialty insurance company
University of Michigan- BPBroadOak Capital Partners
Michigan Rise
ID Ventures
Riverine
Other known investors5 additional known investors
Invest Michigan- JGJohn Gu
Michigan Biomedical Venture Fund
Michigan State University Research Foundation
VITALIZE Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genomenon on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genomenon’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.